Logo

Sanofi Halts the P-III (CARMEN-LC03) Trial of Tusamitamab Ravtansine for Non-Squamous Non-Small Cell Lung Cancer

Share this
Sanofi

Sanofi Halts the P-III (CARMEN-LC03) Trial of Tusamitamab Ravtansine for Non-Squamous Non-Small Cell Lung Cancer

Shots:

  • Sanofi will halt the P-III clinical trial (CARMEN-LC03) assessing tusamitamab ravtansine alone vs docetaxel in previously treated patients with metastatic non-squamous (NSq) NSCLC exhibiting elevated levels of CEACAM5
  • The trial terminated because tusamitamab ravtansine did not show improvement in PFS at the final analysis as evaluated by the Independent Data Monitoring Committee (IDMC) vs docetaxel. Although there was an improvement in OS
  • Tusamitamab ravtansine demonstrated similar safety profile with a lower incidence of significant AEs across various clinical categories

Ref: Sanofi  | Image: Sanofi 

Related News:- Sanofi Announces the Result of Sarclisa (isatuximab)+ KRd in P-III Trial to Treat Multiple Myeloma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions